These findings support a rationale that MSCs genetically engineered with CXCR7 or CXCR7 agonist-primed MSCs are able to enhance the therapeutic potential of MSCs in the treatment of RA (Fig. 7c). The gene discussed is ACKR3; the disease is rheumatoid arthritis.